Organization type

  • Academic research institution
  • Clinical research institution

Early phases

  • Biomarker identification
  • Omics
    • Epigenomics
    • Genomics
    • Proteomics
    • Transcriptomics
  • Target identification – new biological hypothesis
  • Target validation – Hypothesis verification

Screening

  • Assay development
    • In vitro screening models
    • In vivo screening models
  • Chemical libraries
    • Small molecules (including natural product, DNA encoded libraries and fragment libraries)
  • Fragment based screening
    • Hit expansion. Medicinal chemistry programs.

Optimization phases

  • In vitro biochemical models(including assay/model development and testing)
  • In vitro cellular and organotypic 3D models (including assay/model development and testing)
  • In vivo animal models (including assay/model development and testing)
  • Mechanism of action (MoA) assessment
    • Functional cellular panels
    • Omics profiling
    • Selectivity panels
  • Preclinical phase (including assay/model development and testing)(non-regulatory and regulatory)
    • Safety
    • Toxicology

Functional areas

  • Biobanking
  • Bioinformatics
  • Molecular and cellular biology
    • Cell line generation
    • Flow cytometry
    • Gene editing
    • Microarrays
    • Protein expression / purification
    • qPCR
    • RNAseq
    • Sequencing
  • Structural biology

Terapeutic areas

  • Autoimmunity / Inflammation
  • Blood and lymphatic system
  • Cancer
  • Cardiovascular
  • Dermatology
  • Infectious diseases
  • Metabolism / Endocrinology
  • Nervous Central System
  • Ophthalmology / Optometry
  • Rare diseases

Additional activities

  • Consulting services
  • CROs providing no-regulatory and regulatory services for drug discovery